Efficacy of Curcumin for Amelioration of Radiotherapy-induced Oral Mucositis: a Preliminary Randomized Controlled Clinical Trial
Overview
Authors
Affiliations
Background: Oral mucositis (OM) is one of the main problems in almost all patients undergoing head and neck radiotherapy (RT). Owning to the antioxidant and anti-inflammatory properties of curcumin, the effect of both oral and topical formulations of curcumin was assessed on radiation-induced OM (ROM) in this study.
Methods: The safety and efficacy of curcumin mouthwash 0.1% (w/v) and curcumin-nanocapsule were evaluated in ameliorating severity and pain/burning associated with OM during RT. The current randomized, placebo-controlled trial was conducted on 37 patients with head and neck cancers. Patients with grades 1 to 3 of ROM were randomized to receive one of the three interventions: curcumin mouthwash (0.1% w/v); Sinacurcumin soft gel containing 40 mg curcuminoids as nano-micelles (SinaCurcumin®40); or placebo mouthwash with a similar transparent appearance to curcumin mouthwash for 1 min three times daily during RT. Study evaluations were conducted at baseline and weekly thereafter for up to 3 weeks using the Numeric rating scale (NRS) and world health organization (WHO) scale.
Results: Among the 45 patients randomized, 37 (mean (SD) age of 53.36 (15.99) years; 14 [37.8%] women) completed the treatment according to the protocol. Patients treated with either oral or topical curcumin showed a significantly reduced severity and burning related to OM during the first 3 weeks after administration (P-Value < 0.001) as compared with the placebo. At study termination, more than 33% of subjects utilizing curcumin mouthwash and 15% of patients utilizing curcumin-nanocapsule remained ulcer free while all of the placebo-receiving subjects had OM. The reduction of NRS and WHO scale between curcumin groups was comparable without significant differences.
Conclusion: Both curcumin mouthwash and nanocapsule were effective, safe, and well-tolerated in the treatment of radiation-induced OM. Higher doses of curcumin and larger sample sizes can be used for further investigation in future studies.
Trial Registration: https://irct.ir/ IRCT20190810044500N17 (13/08/2021).
The Therapeutic Effects of Curcumin on Oral Disease: A Systematic Review.
Indriyani N, Nuraeny N Clin Pharmacol. 2025; 17:13-24.
PMID: 40034679 PMC: 11874755. DOI: 10.2147/CPAA.S506396.
Vergara D, Sanhueza C, Mendez S, Bustamante M, Vega B, Acevedo F Pharmaceutics. 2025; 17(2).
PMID: 40006548 PMC: 11860046. DOI: 10.3390/pharmaceutics17020181.
Liu X, Zhou Y, Lu Z, Yang F, Wang Y, Zhang S Drug Des Devel Ther. 2024; 18:6223-6241.
PMID: 39722679 PMC: 11669278. DOI: 10.2147/DDDT.S486286.
Orsolic N, Jazvinscak Jembrek M Nutrients. 2024; 16(21).
PMID: 39519572 PMC: 11547968. DOI: 10.3390/nu16213741.
Dipalma G, Inchingolo A, Latini G, Ferrante L, Nardelli P, Malcangi G Antioxidants (Basel). 2024; 13(10).
PMID: 39456414 PMC: 11504953. DOI: 10.3390/antiox13101160.